An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00207116

Enrollment

120

Registered

2005-09-21

Start date

2005-09-30

Completion date

2006-03-31

Last updated

2015-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Keywords

Metastatic Non Small Cell Lung Cancer

Brief summary

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Interventions

DRUGCetuximab

IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Measurable disease tumor available for biopsies * Life expectancy of at least 3 months

Exclusion criteria

* Known or documented brain metastases prior to Cetuximab therapy

Design outcomes

Primary

Measure	Time frame
Prediction of response to Erbitux with non small cell lung cancer	—

Secondary

Measure	Time frame
Radiographic Response	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026